Call for Abstracts for Imedex's 18th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer
San Diego, CA (PRWEB) November 02, 2015
Featuring presentations from more than 25 investigators, Imedex's 18th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer: Recent Advances and Future Directions in Basic and Clinical Cancer Research will take place in sunny San Diego, California on February 4-6, 2016. This annual 2 1/2-day conference to evaluate and discuss basic research and clinical challenges for optimal integration of antiangiogenesis and immune-modulating agents into existing treatment paradigms for cancer care will feature sessions including:
- Update on Angiogenesis
- Update on Tumor Immunology
- Crosstalk in Tumor Immunology and Preclinical Modeling
- Novel Approaches to Activate the Immune Response to Tumor Antigens
- Controversies with New Therapeutics Targeting Angiogenesis and Tumor Immunology
- Biomarkers and Predictors of Response
- Overview of Clinical Trials of Agents Targeting Angiogenesis and Tumor Immunology
Focusing on both clinical and basic research, topics will focus on cutting edge science in the field, highlighting novel strategies under both pre-clinical and clinical development. We encourage clinicians, scientists, and other healthcare professionals who work in the area of tumor immunology to attend.
This symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other healthcare providers (physician assistants, nurses, nurse practitioners), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases.
The outstanding faculty is comprised of over 35 expert specialists and co-chaired by George W. Sledge, Jr., MD, Robert S. Kerbel, PhD, Lee M. Ellis, MD, Axel Grothey, MD, Helen X. Chen, MD, and Mario Sznol, MD. Through didactic presentations, interactive panel discussions, and Q&A sessions, the conference will serve as a platform to discuss and evaluate many of the basic research and clinical challenges for optimal integration of antiangiogenesis and immune-modulating agents into existing treatment paradigms for cancer care, appropriate selection of patients based on biomarker profiles for individualized treatment strategies, and use of these agents in the adjuvant and advanced disease settings.
Shared knowledge makes us stronger. Be a part of this year’s agenda, increase your prestige and gain added exposure for your work by submitting an abstract. Participants interested in presenting data should submit abstracts online by December 15, 2016.
Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management.
Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 100,000 live meeting attendees since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine.®
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb13041337.htm